Our interest is on the use of extended release of protein drugs as well as small bioactive molecules as a research tool for the determination of the effect of focal extended release on brain functions and as therapy for brain disorders.

Local extended delivery of the neurotransmitters, glutamate and TRH in specific sites in the brain has been investigated. It was found that extended localized delivery provided different . In parallel to this investigation we have developed the Gliadel brain tumor implant for treating Glioma multiforme (in clinical use worldwide since its FDA approval in 1996).

New anticancer formulations for direct injection into brain tissue have been developed and being tested for treating brain tumors.

In recent years we focus on the delivery of bioactive agents to the brain through the olfactory via nasal spray. Nanoparticles loaded with TRH have been developed for reducing suicides among US soldiers.

The effect of iron chelators on the treatment of Alzheimer's disease are being investigated. A range of thiosemicarbaside and amino guanidine derivatives are being synthesized and tested for their iron chelation and in vitro and in vivo bioactivity of these compounds.